VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Want to see VYNE full AI Analyst Report?
Total Valuation
VYNE Therapeutics has a market cap or net worth of $22.57M. The enterprise value is -$13.36M.
Market Cap$22.57M
Enterprise Value-$13.36M
Share Statistics
VYNE Therapeutics has 33,352,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,352,860
Owned by Insiders4.27%
Owned by Institutions31.00%
Financial Efficiency
VYNE Therapeutics’s return on equity (ROE) is -0.95 and return on invested capital (ROIC) is -107.15%.
Return on Equity (ROE)-0.95
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-107.15%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee43.85K
Profits Per Employee-2.04M
Employee Count13
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VYNE Therapeutics is ―. VYNE Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio43.53
PB Ratio0.89
Price to Fair Value0.89
Price to FCF-0.75
Price to Operating Cash Flow-1.12
PEG Ratio0.03
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 570.00K and earned -26.48M in profits. Earnings per share was -0.62.
Revenue570.00K
Gross Profit547.00K
Operating Income-29.75M
Pretax Income-26.73M
Net Income-26.48M
EBITDA-26.73M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was -25.74M and capital expenditures 0.00, giving a free cash flow of -25.74M billion.
Operating Cash Flow-25.74M
Free Cash Flow-25.74M
Free Cash Flow per Share-0.77
Dividends & Yields
VYNE Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-32.40%
50-Day Moving Average0.63
200-Day Moving Average0.48
Relative Strength Index (RSI)72.67
Average Volume (3m)2.75M
Important Dates
VYNE Therapeutics upcoming earnings date is Aug 19, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
VYNE Therapeutics as a current ratio of 12.53, with Debt / Equity ratio of 0.00%
Current Ratio12.53
Quick Ratio12.53
Debt to Market Cap0.00
Net Debt to EBITDA0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VYNE Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VYNE Therapeutics EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -0.02.
EV to Sales1.37
EV to EBITDA-0.03
EV to Free Cash Flow-0.02
EV to Operating Cash Flow-0.02
Balance Sheet
VYNE Therapeutics has $24.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of $24.93M billion.
Cash & Marketable Securities$24.93M
Total Debt$0.00
Net Cash$24.93M
Net Cash Per Share$0.75
Tangible Book Value Per Share$0.65
Margins
Gross margin is 98.68%, with operating margin of -5219.12%, and net profit margin of -4646.14%.
Gross Margin98.68%
Operating Margin-5219.12%
Pretax Margin-4689.82%
Net Profit Margin-4646.14%
EBITDA Margin-4689.82%
EBIT Margin-4689.82%
Analyst Forecast
The average price target for VYNE Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-24.96%
EPS Growth Forecast46.11%